Lucid Diagnostics Inc. Common Stock
Market Cap
200M
Short interest (May 15)
3.4%
Net Short (Jun 03 ): 0.0%
Borrow Fee
0.55%
↑ 1.1%
Available Shares
4M
↑ 71.3%
Price Chart
Company Overview
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.